ImmunityBio, Inc. has reported a significant increase in revenue for the second quarter of 2025, with sales reaching $26.4 million, marking a 60% increase from the first quarter of 2025. Year-to-date sales have reached approximately $43 million. Notably, the company has experienced a 246% increase in ANKTIVA unit sales volume in the first half of 2025 compared to the second half of 2024. The net loss attributable to ImmunityBio common stockholders for the six months ended June 30, 2025, was $222.2 million, showing a reduction from the $268.7 million loss during the same period in 2024. This decrease in net loss was primarily attributed to increased product revenue, reduced R&D and SG&A expenses, and lower related-party interest expense. As of June 30, 2025, ImmunityBio's cash position stood at $153.7 million in cash, cash equivalents, and marketable securities. Additionally, the company secured $80 million in equity financing in July 2025, with warrants that could potentially result in additional gross proceeds of up to approximately $96 million.